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There is a paucity of biomarkers in knee osteoarthritis (OA) to inform clinical decision 
making, evaluate treatments, enable early detection and identify people who are 
most likely to progress to severe OA. The absence of biomarkers places considerable 
limitations on the design of research studies, and is a barrier toward applying the 
principles of stratified medicine to knee OA. Here we describe key principles and 
processes of biomarker development and focus on two promising areas that draw 
upon technologies that have only relatively recently been developed for quantitative 
applications in clinical research, namely 3D MRI and acoustic emission. While still at 
an early stage, results to date show promising potential to open up interesting new 
paradigms in this field.
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Developing new biomarkers: general 
principles & approaches
Knee osteoarthritis (OA) is a common but 
heterogeneous condition. The diagnosis of 
knee OA continues to rely heavily on x-radi-
ology, and is based upon a combination of 
characteristic structural features and pain 
symptoms [1]. However, x-ray features corre-
late relatively poorly with pain symptoms [2,3] 
and are of limited value in the early stages. 
In contrast with many other conditions, such 
as rheumatoid arthritis, diabetes and cancer, 
there is a paucity of biomarkers in knee OA 
to inform clinical decision making and to 
enable evaluation of treatments and other 
interventions. Furthermore, there are no bio-
markers either to enable early detection of the 
condition, or to identify people who are most 
likely to progress to severe OA. The absence 
of biomarkers also limits the range of avail-
able research approaches for gaining a better 
understanding of the underlying biology of 
knee OA, and places considerable limitations 
on options for designing studies to evaluate 
new treatments, such as cartilage regenera-
tion. Also, given the recognized clinical and 
biological heterogeneity of knee OA, there 
is an urgent need for biomarkers to enable 
the principles of stratified medicine to be 
explored and applied for this condition.
Biomarkers are characteristics that are 
‘objectively measured and evaluated as 
indicators of normal biological processes, 
pathogenic processes or pharmacologic 
responses to a therapeutic intervention’ [4,5]. 
This definition allows biomarkers to be 
either numerical (e.g., joint space width/
mm; volume of medial tibial cartilage/ml) 
or categorical (e.g., Kellgren-Lawrence (KL) 
grade; MOAKS synovitis score [6]), so long as 
they are objectively measured. In principle, 
a perfect biomarker correctly predicts clini-
cal outcome [7]. Since no biomarker is per-
fectly valid, investigation and development of 
a new candidate biomarker involves a wide 
range of activities to ensure that the uncer-
tainty, risk and cost in making research or 
clinical decisions reliant on the biomarker 
can be m anaged. Such activities involve:
•฀ Technical validation, based on the concept 
that measurements made anywhere in the 
world should be identical or acceptably 
similar. These activities can be subdivided 
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into repeatability, reproducibility and availability. 
Repeatability is the idea that measurements should 
be similar when made on the same person, by the 
same operator, using the same equipment and soft-
ware, in the same setting, over a short period of 
time. Reproducibility is the idea that measurements 
should be similar when made on equivalent subjects, 
by different operators, using different equipment, in 
different settings, at different times. Availability is 
the idea that there are no legal, ethical, regulatory 
or commercial barriers preventing measurement in 
particular settings or jurisdictions. Technical valida-
tion does not, of itself, provide any evidence that the 
biomarker is useful. However, it is a prerequisite for 
large multicenter studies or meta-analyses.
•฀ Biological and clinical validation, based upon 
the concepts that the biomarker should faithfully 
represent underlying biology, and accurately fore-
cast clinical outcome. This has been described as 
a ‘graded evidentiary process’ dependent on the 
intended application [8]. Biological validation does 
not, of itself, assume that the biomarker can be 
robustly measured in multiple centers.
Much of the academic and regulatory literature on 
biomarker validation aligns with ‘biospecimen’ bio-
markers derived from patients’ tissues or biofluids, 
where the biomarker is a specified molecular entity 
whose measurement is essentially an exercise in ana-
lytical biochemistry. However, there is considerably 
less literature regarding validation of ‘biosignal’ bio-
markers from, for example, imaging, acoustic emission 
or electrophysiology. Biospecimen biomarkers are typi-
cally measured using a dedicated in vitro diagnostic 
device remote from the patient, where the device’s per-
formance can be optimized on historical or biobanked 
samples. For biosignal biomarkers on the other hand, 
technical quality depends mainly on how the measure-
ment is performed while the patient is physically pres-
ent and coupled to the in vivo diagnostic device. Bio-
signal repeatability may be relatively easily achieved, 
allowing small studies by a single investigator. How-
ever, multicenter reproducibility is often challenging, 
because of the need for training and standardization of 
the biosignal device and its use in each setting.
For biospecimen biomarkers, both in guidelines 
and in actual practice, technical (assay) validation can 
mostly be achieved at a fairly early stage, possibly with 
some early clinical validation from biobanked samples 
where the patient outcome is known. The biomarker 
already has great credibility before a single new patient 
is recruited. For biosignal biomarkers, on the other 
hand, a stepwise approach [9], where small increments 
of technical and biological–clinical validation are 
addressed in parallel, is more appropriate. Early stud-
ies address repeatability in single centers, or in a few 
centers using identical equipment. At the same time, 
biological and clinical validity may be approached ten-
tatively using the Bradford Hill [9–11] criteria, for exam-
ple with small cross-sectional or interventional studies. 
Only later, after extensive efforts to establish that the 
biomarker measures are the same in different centers, 
using different equipment in different jurisdictions, 
can definitive outcome studies be performed.
Developing new biomarkers: key statistical 
issues
As described above, the process for developing and val-
idating new biomarkers is complex and multistaged. 
Broadly speaking, the key statistical issues that arise in 
any study aimed at developing a novel biomarker for a 
chronic condition depend crucially upon the stage of 
biomarker development on which the study is focused. 
Among these, however, the following are highlighted 
as being particularly important questions in relation 
to this issue:
Is the candidate biomarker repeatable & 
reproducible?
In the early stages of biomarker development, the focus 
may be on repeatability and reproducibility, in other 
words, roughly speaking, S/N ratio, where ‘noise’ can 
encompass technical variation in the measurement 
device, short-term, clinically irrelevant biological varia-
tion in the patient, and variation between multiple 
observers.
How does the candidate biomarker compare 
with other biomarkers?
Once a candidate biomarker has passed the initial test 
described above, the next step focuses on comparing it 
in cross-sectional studies with other, more established, 
biomarkers for the same condition. An important issue 
is then the level of validity of the current default bio-
marker as a ‘gold standard’. If the validity of the cur-
rent ‘gold standard’ biomarker is high (i.e., approach-
ing the Prentice criteria for surrogacy), the candidate 
biomarker will likely be judged by the extent to which 
it can (almost) match the current default’s predictions 
but at substantially lower cost or greater convenience. 
If, however, the validity of the current biomarker is rel-
atively low, the emphasis for the candidate biomarker is 
more likely to be on improving predictive performance.
Can the candidate biomarker predict clinical 
outcomes?
In either case, if the candidate biomarker is still in 
the frame after initial testing, its most severe test is its 
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ability to predict important clinical outcomes, so as to 
justify its use either as a surrogate end point in clinical 
trials, or for use in clinical practice, perhaps to allow an 
intervention intended to reverse, or at least slow, clini-
cal progression. A good example of a biomarker that 
has proven value as an early indicator of the need for 
clinical action is the rate of change in serum creatinine 
as a biomarker for incipient renal failure [12,13].
Surrogate end points have a chequered history. In 
the statistical literature, the widely cited ‘Prentice cri-
teria’ for surrogacy [7] are very difficult to establish 
in practice. In particular, establishing a correlation 
between a health outcome and a biomarker is far from 
sufficient to establish surrogacy [14]. In the medical 
literature, Psaty et al. [15] discuss how treatments that 
appear beneficial on the basis of a surrogate end point 
can later prove to have a harmful effect on the relevant 
clinical end point.
Modern technological developments are increas-
ingly opening up new possibilities for biomarker dis-
covery. Traditionally, the term ‘biomarker’ would refer 
to a direct biophysical or biochemical measurement. 
Nowadays, however, the term can include summary 
descriptors of an intrinsically high-dimensional object, 
such as a digital image, a time series or a chemical spec-
trum, termed ‘biosignals’. Our work to explore acoustic 
emission (AE) as a biomarker for knee OA [16–19] illus-
trates some of the challenges which are being raised 
by the ever-broadening scope of technologies being 
explored as potential biosignals.
As described below, the raw data from an AE time 
series consist of a record of noise levels recorded 
from knees throughout a person’s sit-stand-sit move-
ment. Low levels of AE are potentially contaminated 
by background noise. For this reason, the recording 
equipment stores only AE levels that exceed a prespeci-
fied threshold. Each such exceedance is termed a ‘hit’. 
Potential biomarkers include the frequency and posi-
tions of hits, or summary statistics of the real-valued 
time series of AE levels during each hit. Formally, this 
defines a ‘marked point process’, in which the points 
are the onset times for each hit, while the marks are the 
associated time series of AE levels throughout the cor-
responding excursions over the threshold. The statisti-
cal challenge is to formulate and fit to this complex, 
very high-dimensional object, a model that effects a 
dramatic reduction in dimensionality from the data to 
a set of parameter estimates or summary statistics that 
capture the essential properties of the data.
Once a set of summary statistics has been identified, 
the next step is to analyse the components of variation 
in each. Typically, these can include systematic varia-
tion between identifiably different groups, for exam-
ple people with the condition compared with healthy 
controls, and a hierarchy of random components of 
variation: between people in the same group; between 
repeat series on the same person at different times; 
technical variation between ostensibly equivalent 
pieces of equipment and inherent statistical variation 
in the summary statistics (measurement error). Repro-
ducibility requires that variation between groups and 
between patients within groups should dominate varia-
tion between times within patients, technical variation 
and inherent statistical variation.
This has direct implications for study design. A min-
imal requirement is that the design includes replication 
at each level of the hierarchy so that all of the variance 
components are identifiable. The more ambitious goal 
of a formal sample size calculation to guarantee accept-
able levels of precision in the estimated components of 
variation is only feasible if the different phases are con-
ducted as separate studies, with the results of the ini-
tial study informing the sample size for the subsequent 
validation study.
When a candidate biomarker has passed the devel-
opment phase, it can then be tested in further work to 
determine whether it can predict, with practically use-
ful accuracy, a clinically relevant end point. To avoid 
the danger of overfitting, the data used for this clinical 
validation phase must be separate from the data used 
in the development phase. This can be achieved either 
by a formal separation into two independent studies, or 
by dividing the data into two subsets. For the same rea-
son, direct comparison of a candidate biomarker with 
the clinically relevant end point should be reserved for 
the clinical validation phase. In our studies, candidate 
biomarkers are being developed based on properties of 
the AE signals that can discriminate between painful 
and pain-free knees, and between other current mark-
ers of severity. Clinical validation against disease pro-
gression will require longer term follow-up studies.
Developing new biomarkers for knee OA
In knee OA, the current unmet need is for biomarkers 
which can improve our forecast of clinical outcomes. 
For example, can we predict who will respond well to 
NSAIDs, and who will suffer worsening pain and dis-
ability leading to early knee replacement? Can we pre-
dict which people will benefit most from knee replace-
ment? Can we identify specific cohorts (stratified 
medicine) who will benefit from interventions such as 
insoles or high tibial osteotomy, or from investigational 
new drugs?
Imaging biomarkers based on radiographic features, 
particularly KL scores, have played a central role in 
OA research, response assessment and predicting clini-
cal outcome for many years. Other imaging modali-
ties are currently emerging, including CT scanning, 
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Figure 1. 3D MRI of knee without osteoarthritis. 
Representative example of healthy knee with 
no evidence of knee osteoarthritis (patella not 
shown). Articular cartilage (pink) covers whole of 
the articulating surface, there is no evidence of 
osteophytes around the cartilage plates, and the 
menisci are full sized.
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arthroscopy, PET, single-photon emission computed 
tomography/scintigraphy, ultrasound and MRI. Of 
these, MRI is particularly promising and offers the 
prospect of using quantitative measures as biomarkers 
from several tissues and structures involved in the dis-
ease process [20,21], and of demonstrating moderately 
good correlation with symptoms [22–25]. MRI has the 
important advantage of avoiding the need for ionizing 
radiation and of being reasonably widely available for 
use in clinical trials, although it is difficult to use for 
population- and primary care-based studies. Therefore, 
there continues to be a need to explore other potential 
approaches as well.
Given the paucity of robust biomarkers within this 
field, and the heterogeneity and slow rate of change of 
the condition, the development and validation of a new 
biomarker necessarily requires work to be conducted 
over several years, and to include the use of large-scale 
longitudinal studies to inform its adoption. Further-
more, depending on the characteristics of the candidate 
biomarker, it may prove extremely difficult to fully test 
a candidate biomarker with the necessary stringency to 
fully satisfy the requisite criteria. N evertheless, while 
this is clearly a very challenging field, encouraging 
progress is being made in terms of investigating new 
candidates. The two approaches described here dem-
onstrate potential not only as useful additions to the 
range of available biomarkers, but also to offer new 
paradigms for measuring and studying knee OA.
3D MRI
The increased availability of magnetic resonance scan-
ners in recent years has enabled a number of potential 
imaging biomarkers for knee OA to emerge. Broadly 
speaking, there are two approaches to the measure-
ment and interpretation of MRIs of the knee for this 
purpose:
•฀ Categorical, often semi-quantitative scales such as 
BLOKS and MOAKS [6].
•฀ Quantitative methods [26].
The primary advantages of semi-quantitative scor-
ing systems are that they consider the whole knee 
instead of focusing on individual tissues, and exploit 
the proficiency of expert readers to judge the condition 
of the whole knee. Their primary disadvantage is that 
they are time consuming to perform, and demanding 
for the readers. A further disadvantage is that these 
scales have multiple subscales, and it is not at all clear 
whether and how these subscales should be combined.
To date, most of the published work involving quan-
titative change in the knee has focused on changes in 
the morphology of articular cartilage in the femoro-
tibial joint. Changes in cartilage thickness and vol-
ume have been extensively reported (for example, [27]). 
These changes have been shown to be responsive, and 
to predict future OA progression, as well as risk of total 
knee replacement, and are weakly associated with clin-
ical symptoms such as pain.
Recently, changes in 3D bone shape have been 
reported in a large group of OA patients, and shown 
to be more responsive than changes in cartilage [28] 
thickness and radiographic joint space width. Bone is 
known to change with the progression of OA, and the 
tibial condyles have demonstrated an increase in bone 
area [29,30].
Several other imaging biomarkers have been sug-
gested, and are being actively pursued, including bone 
marrow lesions, meniscal volume and extrusion, and 
synovitis. It is not yet known how each of these tissues 
change with time, and with extent of disease, and how 
they interact with each other. Each of these imaging 
biomarkers share common features. OA is a slow-mov-
ing disease, and the amount of change which occurs 
www.futuremedicine.com 291
Osteophytes
Denuded articular
cartilage
Medial meniscus
reduced in size
Figure 2. 3D MRI of knee with osteoarthritis. 
Representative example of osteoarthritis knee. 
Articular cartilage is characteristically denuded in 
the medial femorotibial joint. Osteophytic growth is 
apparent around most of the femoral cartilage, most 
prominently on the medial side, and the menisci are 
smaller in size, possibly as a result of previous meniscal 
surgery.
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Figure 3. Joint angle-based acoustic emission.
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within a clinical study (typically of 1 year’s duration) is 
very small. For example, cartilage thickness changes by 
fractions of 1 mm per year on average, when the total 
thickness is only 3–5 mm. This amount of change rep-
resents about a quarter of the width of a single pixel 
on the screen. Measuring such small changes is a chal-
lenge. It requires painstaking work, excellent measure-
ment tools and the use of very large patient cohorts to 
establish statistical significance.
Interpretation of imaging biomarkers in terms of 
clinical outcomes is also challenging. The relation-
ship of small changes in tissues does not correlate well 
with clinical outcomes, such as pain. Interpretation of 
imaging biomarkers and their relationship to patient 
outcomes therefore requires a thorough approach and 
careful analysis. Examples of 3D magnetic resonance 
images for knee OA are shown in Figures 1 and 2.
Acoustic emission
In recent years there has been increasing interest in 
translational applications of acoustic science to inform 
the diagnosis and management of several different 
health [31–39] and dental conditions [40,41]. In this con-
text, the development of techniques to measure high-
frequency AE in knee joints [16–19] offers the potential 
to develop a biomarker reflecting the integrity of inter-
actions between knee joint components during weight-
bearing movement. Since OA affects joint function, 
markers which assess or reflect the integrity of interac-
tions between joint structures during knee movement 
offer a strong rationale for biomarker development.
Noninvasive, portable systems have been developed 
to capture and analyse high-frequency sound emitted 
during weight-bearing knee movement, involving the 
translation of leading-edge AE technology into clini-
cal applications. Wide-band AE sensors detect sound 
waves with frequencies up to 200 kHz emitted from 
knees during sit-stand-sit movement. Similar prin-
ciples have been widely utilized for many years in 
nondestructive testing and condition monitoring of 
engineering structures for early detection of damage 
and material defects. By analogy, surfaces which are 
smooth and well lubricated move quietly against each 
other, whereas rough, poorly lubricated surfaces move 
unevenly, producing acoustic signals.
AE sensors are piezoelectric transducers which are 
attached to knee surfaces, using defined anatomical 
landmarks, to record short bursts of acoustic energy 
generated by stress upon, and friction between, joint 
components during weight-bearing movement.
Data collection involves simultaneous recording of 
weight distribution, joint angle and acoustic emissions 
from both knees using a ‘Joint Acoustic Analysis Sys-
tem’. AE sensors are positioned anterior to the medial 
patellar retinaculum and attached to ensure a good 
connection between source and sensor. Electrogoni-
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Figure 4. Acoustic emission events in four movement phases in each subgroup. 
Group H1: 10 healthy knees from early adulthood aged between 22 and 40 years (mean: 29.00 years; SD: 5.45 
years). 
Group H2: 11 healthy knees from middle adulthood aged between 42 and 58 years (mean: 50 years; SD: 5.07 
years). 
Group H3: 13 healthy knees from late adulthood aged over 61 years (mean: 71.27; SD: 6.99 years) (Figure from [18]). 
Group OA1: 7 OA knees from middle adulthood aged between 52 and 58 years (mean: 55.00 years; SD: 1.9 years). 
Group OA2: 12 OA knees from late adulthood aged over 61 years (mean: 69.5 years; SD: 6.39 years). 
AA: Ascending–acceleration phase; AD: Ascending–deceleration phase; DA: Descending–acceleration phase; 
DD: Descending–deceleration phase denoted by DD; SD: Standard deviation.
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ometers are positioned laterally to each knee, along the 
plane between the greater trochanter and lateral mal-
leolus. AE, joint angle and ground reaction forces are 
recorded while participants perform a set of sit-stand-
sit movements, starting in a seated position with their 
back against the chair and knees bent at 90 degrees. 
Each test involves two sets of five sit-stand-sit move-
ments. This protocol has been found not only to gener-
ate meaningful data but also to be convenient, feasible 
and acceptable for use in clinical settings.
AE signals are characterized by short-duration burst 
waveforms. AE data acquisition operates in an event-
based recording mode to minimize data volume, and a 
burst signal must have a significant amplitude in order 
for it to be recorded as an AE event or AE hit. As an 
example, the AE events recorded over five repeated sit-
stand-sit movements from a person are shown as dots 
superimposed on the joint angle signal (solid curve) in 
Figure 3, where the AE waveform for one of the AE 
events is also shown.
Whereas traditional imaging techniques reflect 
the static anatomical appearance of knee joints at a 
particular posture, AE captures dynamic interaction 
among joint components as a result of movements. 
Each movement action is divided further into its con-
stituent phases, such that each sit-stand-sit cycle is 
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Figure 5. Image-based representation of typical acoustic emission feature profiles. Image-based representation is 
divided into four quadrants: 
Left quadrants show the AE feature profile of the ascending phase. 
Right quadrants show the AE feature profile of the descending phase. 
Top quadrants show the AE feature profile of the acceleration phase. 
Bottom quadrants show the AE feature profile of the deceleration phase. 
Within each quadrant, the co-occurrence of AE peak magnitude and ASL values are shown as interval-based 2D 
histograms with the horizontal axis representing ASL and the vertical axis representing AE peak magnitude.  
Figure reproduced with permission from [18].  
AE: Acoustic emission; ASL: Average signal level.
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divided into the ascending phase (corresponding to 
the sit-to-stand movement) followed by the descend-
ing phase (corresponding to the stand-to-sit move-
ment). Using this two-phase movement model and 
the average number of AE events per each movement 
phase, the ascending phase shows the largest differ-
ence between young healthy knees and old OA knees. 
At a finer level, the peak angular velocities derived 
from the joint angle signal are used to divide each 
ascending phase and each descending phase into the 
acceleration phase followed by the deceleration phase, 
yielding a four-phase movement model for each sit-
stand-sit cycle.
Figure 4 shows differences in the number of AE 
hits in each of four movement phases for five differ-
ent groups, namely healthy knees from early adult-
hood (H1), healthy knees from middle adulthood 
(H2), healthy knees from late adulthood (H3), OA 
knees from middle adulthood (OA1) and OA knees 
from late adulthood (OA2). Within this group, the 
least overlap between the five subgroups occurred in 
the de scending-deceleration (DD) phase of movement.
In order to discover biomarkers, it may be useful 
to take into account the characteristics of the wave-
forms which constitute each AE hit. A wide range of 
waveform features could be used to describe the char-
acteristics of an AE hit. These include amplitude (peak 
amplitude value of the AE waveform; average signal 
level [ASL] over waveform duration), energy (sum of 
absolute or squared amplitude values over waveform 
duration), frequency (peak frequency of waveform; 
center and average frequencies over the entire wave-
form duration; initiation and reverberation frequen-
cies of the waveform before and after the peak) and 
time (duration of the AE waveform, waveform rise and 
fall time before and after the peak). Among various 
AE features investigated to date, AE peak magnitude 
and ASL have shown good discrimination between 
subgroups, particularly in the descending-deceleration 
movement phase.
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Image-based representation has been developed to 
display the value distributions of AE peak amplitude 
and ASL features from each knee in each movement 
phase, thereby allowing visual comparison of different 
knee joint conditions. Typical AE feature profiles of a 
knee in each group are shown in Figure 5, in which col-
ors and numerical values indicate the average number 
of AE hits in each co-occurrence class per movement 
phase based on two sets of five repeated sit-stand-sit 
movements. A healthy knee joint in early adulthood 
(from Group H1) generates a small number of AE 
hits of lower peak amplitude and ASL values. As age 
increases, the number of AE hits increase with increas-
ing higher peak amplitude and ASL values (Groups 
H2 and H3). OA knees generate the highest number 
of AE hits with a wide range of peak magnitude and 
ASL values. Furthermore, there are differences in the 
AE feature profiles between OA knees. AE events with 
high ASL and low peak amplitude (corresponding to 
relatively long duration and low magnitude waveforms) 
occur in the ascending-acceleration movement phase 
for the OA1 knee and in the descending-acceleration 
movement phase for the OA2 knee.
Through image-based AE feature profiles, diverse 
AE occurrences and waveform characteristics are 
represented in a uniform information format which 
allows conventional multivariate statistical analysis 
techniques to be applied to reveal hidden cluster struc-
tures without using prior knowledge. One of the most 
widely used unsupervised methods is principal com-
ponent analysis (PCA), which is applied to transform 
a large set of co-occurrence classes in the image-based 
AE feature profile into a small set of relatively inde-
pendent variables, known as principal components, in 
such a way as to highlight the differences and similari-
ties among the measured knee joints.
For example, Figure 6 shows the projection of AE fea-
ture profile based on two sets of five repeated sit-stand-
sit movements from 53 knee joints to the space defined 
by the first three principal components, which capture 
approximately 87.97% of the total variance in the data. 
By labeling each point projected from each AE feature 
profile according to its age and knee condition group, five 
well-separated clusters are seen with a trajectory related 
to knee age and condition, progressing from Group H1 
to Group H3, followed by Group OA1 to OA2. Fur-
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thermore, this trajectory shows increasing areas for each 
cluster, starting from the smallest cluster for Group H1. 
With increasing age, cluster areas increase with longer 
distances among the feature profiles for Groups H2 and 
H3. In changing from healthy to OA, the cluster areas 
spread even further with longer distances among the 
projected AE feature profiles of Group OA1 compared 
with Group H3. Late adulthood OA knees produce the 
largest cluster area with the widest spread of the pro-
jected AE feature profiles. By using the clusters and tra-
jectory in the PCA space as the reference, the condition 
of a knee can be judged visually based on the projected 
point of its AE profile along the trajectory and its dis-
tance with respect to the center and boundary of the 
nearest two clusters, and a single quantitative measure 
can be given based on its PCA coordinates.
These results demonstrate the potential of AE as a 
biomarker in knee OA. AE offers not only an objec-
tive, quantitative measurement tool but also a new par-
adigm for knee OA assessment and biomarker devel-
opment. The system is also noninvasive, portable and 
convenient to use. While a full understanding of the 
tissue origin of acoustic signals in knee joints awaits 
further investigation, the findings to date suggest that 
it may have several potential applications in primary 
and secondary care settings.
Conclusion & future perspective
Among the increasing array of emerging candidate 
biomarkers for knee OA, 3D MRI and AE are based 
on novel principles and technologies, and have dem-
onstrated particularly promising potential for a wide 
range of applications in research and clinical practice. 
Currently, studies to assess the precision, sensitivity and 
inter/intra-user reproducibility of AE and MR imaging 
compared with radiographic KL scores are underway. 
The outcome of this work will provide an indication 
of the performance of this approach in assessing OA 
severity compared with the current ‘gold standard’ 
radiographic assessment. Following further valida-
tion of these novel technologies through large-scale 
prospective studies, they may be developed to support 
stratified approaches for designing clinical trials of new 
treatments and interventions as well as providing ear-
lier outcome measures for use in such studies.
In clinical practice they may offer the potential to 
develop approaches for early identification of people at 
risk of progressing-to-severe knee OA, and to develop 
and deliver personalized treatment approaches, as well 
as to monitor the efficacy of interventions. Further-
more, both approaches have potential for use in other 
affected joints. The extent to which 3D MRI and AE 
will qualify for use as biomarkers in these, and other, 
applications remains to be determined. Nevertheless, 
the fact that this, and other work in this field, is pro-
gressing promisingly suggests that robust biomarkers 
for knee OA are at last becoming a feasible prospect.
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Executive summary
•฀ While the paucity of biomarkers for knee osteoarthritis continues to constrain progress in developing new 
treatments for this condition, several promising approaches for biomarker development are beginning to 
emerge.
•฀ New approaches and technologies being used for biomarker development in knee osteoarthritis also have 
potential to inform new paradigms about this condition for application in clinical practice and research.
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